PT  - JOURNAL ARTICLE
AU  - Nörz, Dominik
AU  - Grunwald, Moritz
AU  - Olearo, Flaminia
AU  - Fischer, Nicole
AU  - Aepfelbacher, Martin
AU  - Pfefferle, Susanne
AU  - Lütgehetmann, Marc
TI  - Evaluation of a fully automated high-throughput SARS-CoV-2 multiplex qPCR assay with build-in screening functionality for DelHV69/70- and N501Y variants such as B.1.1.7
AID  - 10.1101/2021.02.12.21251614
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.02.12.21251614
4099  - http://medrxiv.org/content/early/2021/02/18/2021.02.12.21251614.short
4100  - http://medrxiv.org/content/early/2021/02/18/2021.02.12.21251614.full
AB  - Background New SARS-CoV-2 variants with increased transmissibility, like B.1.1.7 from England or B1.351 from South Africa, have caused considerable concern worldwide. In order to contain the spread of these lineages, it is of utmost importance to have rapid, sensitive and high-throughput detection methods at hand.Methods Analytical sensitivity was assessed for both wild-type SARS-CoV-2 and B.1.1.7 lineage by serial dilution. A total of 141 clinical samples were subjected to the test and results compared to a commercial manual typing-PCR assay and NGS.Results The multiplex assay is highly sensitive for detection of SARS-CoV-2 RNA in clinical samples, with an LoD of 25.82 cp/ml (CI: 11.61 – 57.48). LoDs are slightly higher for the HV68/70 deletion (111.36 cp/ml; CI: 78.16 – 158.67) and the N501Y SNP (2548.04 cp/ml, CI: 1592.58 – 4076.73). A total of 141 clinical samples were tested with the assay, including 16 samples containing SARS-CoV-2 of the B.1.1.7 lineage. Three non-B.1.1.7 samples contained a HV69/70 deletion. All were correctly identified by the multiplex assay.Conclusion We describe here a highly sensitive, fully automated multiplex PCR assay for the simultaneous detection of del-HV69/70 and N501Y that can distinguish between lineages B.1.1.7 and B1.351. The assay allows for high-throughput screening for relevant variants in clinical samples prior to sequencing.Competing Interest StatementML received speaker honoraria and related travel expenses from Roche Diagnostics.All other authors declare no conflict of interest.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work was conducted in accordance with paragraph 12 of the Hamburg hospital law (paragraph 12 HmbKHG). The use of anonymized samples was approved by the ethics committee, Freie und Hansestadt Hamburg, PV5626.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesUpon request